.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Researchers from the Indian Institute of Technology Kanpur (IIT-K) made a significant breakthrough in oncology. Specifically, they identified a key driver of colorectal cancer chemotherapy resistance. This discovery could reshape treatment strategies for patients who fail standard therapies.
Prof Bushra Ateeq from the Department of Biological Sciences and Bioengineering led this collaborative study. Her team worked alongside experts from Tata Memorial Centre, King George's Medical University, and Henry Ford Health System. Consequently, they found that the protein DKC1 plays a pivotal role in cancer cell survival. Previously, scientists only associated DKC1 with basic cell growth and aging. However, this study reveals its active role in protecting tumors from therapeutic agents.
How does this protein help tumors survive? Under normal conditions, damaged or unhealthy cells undergo a natural self-destruction process called apoptosis. However, high levels of DKC1 allow cancer cells to bypass this critical cellular machinery. Furthermore, DKC1 regulates specialized fat molecules, particularly sphingolipid biosynthesis. This dysregulation alters lipid production, helping the tumor grow rapidly. Consequently, cancer cells become highly resistant to standard chemotherapy regimens like FOLFOX.
During laboratory trials, researchers successfully blocked the signaling pathways associated with DKC1. This intervention significantly slowed tumor growth. Additionally, it made the cancer cells highly sensitive to chemotherapy once again. Importantly, clinical findings from patients confirmed that high DKC1 levels correlate with advanced disease stages. Therefore, patients with elevated DKC1 often face much poorer survival rates.
Q1: What is the main finding of the IIT Kanpur study?
The study identified that the protein DKC1 drives colorectal cancer chemotherapy resistance. It does this by dysregulating fat production and helping cancer cells bypass self-destruction.
Q2: How can DKC1 serve as a biomarker in clinical practice?
Oncologists can use DKC1 levels to identify patients likely to resist routine chemotherapy. Therefore, these patients can receive targeted therapies instead of ineffective treatments.
Q3: Which institutions collaborated on this research?
The study was spearheaded by IIT Kanpur in collaboration with Tata Memorial Centre, King George's Medical University, and Henry Ford Health System.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Researchers at IIT Kanpur have identified that the DKC1 protein drives colorectal cancer chemotherapy resistance, opening doors for targeted therapy....
5 months ago
A prospective multicenter cohort study demonstrates that baseline health-related quality of life, particularly physical functioning, independently predicts all-cause maintenance hemodialysis mortality. Assessing patient-reported outcomes provides vital prognostic value beyond standard biochemical markers.
Today
Delhi is undergoing a major healthcare overhaul with enhanced Ayushman Bharat insurance up to ₹10 lakh, increased MBBS and PG medical training seats, expanded primary network mandirs, new tertiary neuro-ICUs, and public-private reproductive technology initiatives to build a resilient, preventative healthcare model.
Today
Aon forecasts India's healthcare inflation will ease to 10.1% in 2027 from 11.5% in 2026. Despite moderation, healthcare expenses continue to outpace general inflation, propelled by non-communicable diseases, advanced medical therapeutics, and expanding utilization patterns across diverse patient populations.
Today
Non-union fractures occur in 2-5% of cases, causing significant disability and cost. Conservative modalities such as LIPUS, PEMF, and focused ESWT offer non-surgical healing options for defects up to 5-10 mm when adequate mechanical stability exists without infection.
Today
Explore how novel oxygen-releasing PVA hydrogels prevent early post-transplant hypoxic damage in pancreatic beta cells, sustaining viability and insulin secretory function.
Today
